Article Text

PDF
PP 051
PULMONARY HYPERTENSION IN PAEDIATRIC PATIENTS: DATA FROM THE COMPERA-KIDS REGISTRY
  1. Matthias Gorenflo1,
  2. David Pittrow2,
  3. Dörte Huscher3,
  4. Victoria Ziesenitz4,
  5. Joseph Pattathu4,
  6. Alexander Praus5,
  7. Peter Ewert5,
  8. Harald Kaemmerer1,5,
  9. COMPERA-Kids Steering Committee Study Group
  1. 1COMPERA-Kids Steering Committee and University Hospital Heidelberg
  2. 2Technical University Dresden
  3. 3German Rheumatism Research Centre & Charité, Berlin
  4. 4University Hospital Heidelberg
  5. 5German Heart Centre Munich

Abstract

Background Pulmonary hypertension (PH/PAH) can have many possible causes in childhood. The aim of the COMPERA registry is the characterization of patients of all ages with PH/PAH and their treatment patterns.

Methods Since June 2013, paediatric patients can be included in the COMPERA registry (ClinTrials.gov: NCT01347216) which has originally been established for adult patients with pulmonary hypertension in 2007.

Results Until 2015, 78 patients <18 years (47 Pat <6 years) with pulmonary hypertension were enrolled, of whom 65.4% had PAH due to congenital heart disease (PAH-CHD), 25.6% had idiopathic PAH (iPAH), 3 had persistent PH of the newborn, 2 had PH associated with interstitial lung disease, and two had other PH. The patients were 6.1±6.0 years old, 52.6% girls; NYHA functional class I/II in 55.0%, and III in 42.3%. Mean disease duration after diagnosis was 37.7±55.8 months. Right heart catheterization data were available for 82.1% of the patients. Mean pulmonary artery pressure was 42.8±19.4 mmHg, right atrial pressure was 8.0±8.8 mmHg, cardiac index was 3.6±1.2 l/min/m2. Monotherapy was received by 65.4% of the patients whereas 33.4% of the patients had combination therapy. Phosphodiesterase-5 inhibitors (PDE5I) were administered to 76.9% of the patients, 35.9% of the patients received endothelin receptor antagonists and 3.8% received prostacyclins. About 24% of patients received anticoagulation therapy.

Conclusion The most common form of PH in this study cohort is PAH-CHD, followed by iPAH. Treatment options for children primarily comprise PDE5I. Only a small number of paediatric patients receive anticoagulation therapy.

  • ESDP

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.